NEXT: Nicole Boice, Global Genes, Discusses the Future of Rare Disease

November 18, 2019

Nicole Boice, founder of Global Genes, discusses the future of rare disease and the challenges that will need to be addressed in this brief interview. It was filmed during the Global Genes’ 2019 Rare Patient Advocacy Summit in September 2019. It coincided with the release of Global Gene’s report NEXT: Imagining the Future of Rare Disease

Drug Development

FDA Lifts Partial Clinical Hold on IND for EryDel’s Phase 3 Therapy for Ataxia-Telangiectasia

Rare Daily Staff Quince Therapeutics said that The U.S. Food and Drug Administration has lifted the partial […]

Drug Development

FDA Approves Amicus’s New Treatment for Adults with Late-Onset Pompe Disease

Rare Daily Staff The U.S. Food and Drug Administration has approved Amicus Therapeutics’ Pombiliti + Opfolda, a […]

Drug Development

Ionis’s Eplontersen Phase 3 Results Show Consistent and Sustained Benefit in Patients with ATTRv-PN

Rare Daily Staff Ionis Pharmaceuticals reported that The Journal of the American Medical Association published positive results […]

Strategy

PTC Cuts 25 Percent of Workforce in Further Strategic Prioritization

Rare Daily Staff Rare disease focused biotech PTC Therapeutics announced further strategic prioritization and an associated workforce […]

Finance

Capricor Raises $23 Million in Registered Direct Offering

Rare Daily Staff Capricor Therapeutics said it has raised $23 million, which it will use to fund […]

Drug Development

FDA Expands Approved Uses of Pfizer Drug to Include Childhood Leukemia

Rare Daily Staff The U.S. Food and Drug Administration expanded the approval of Pfizer’s Bosulif to include […]

Deals

Théa Terminates Plans to Acquire ProQR Assets

Rare Daily Staff RNA therapy developer ProQR Therapeutics said that Laboratoires Théa’s previously announced agreement to acquire […]

Finance

Soleno Therapeutics Raises $120 Million After Reporting Positive Prader-Willi Trial Results

Rare Daily Staff Two days after reporting positive top-line results of its experimental treatment for Prader-Willi syndrome, […]

Drug Development

FDA Grants Priority Review for Merck’s Sotatercept to Treat Adults with Pulmonary Arterial Hypertension

Rare Daily Staff The U.S. Food and Drug Administration (accepted for priority review a new Biologics License […]

Stay Connected

Facebook Twitter Instagram Youtube

NEXT: Nicole Boice, Global Genes, Discusses the Future of Rare Disease

Related

FDA Lifts Partial Clinical Hold on IND for EryDel’s Phase 3 Therapy for Ataxia-Telangiectasia

FDA Approves Amicus’s New Treatment for Adults with Late-Onset Pompe Disease

Ionis’s Eplontersen Phase 3 Results Show Consistent and Sustained Benefit in Patients with ATTRv-PN

PTC Cuts 25 Percent of Workforce in Further Strategic Prioritization

Capricor Raises $23 Million in Registered Direct Offering

FDA Expands Approved Uses of Pfizer Drug to Include Childhood Leukemia

Théa Terminates Plans to Acquire ProQR Assets

Soleno Therapeutics Raises $120 Million After Reporting Positive Prader-Willi Trial Results

FDA Grants Priority Review for Merck’s Sotatercept to Treat Adults with Pulmonary Arterial Hypertension

Stay Connected